Besides, SLC30A2 and SLC30A8 predicted poorer prognosis in both intestinal and diffuse type patients and high expression of SLC30A3 and SLC30A10 correlated with poor prognosis in intestinal, mixed type GC patients, respectively. Here, SLC30A2 is linked to gastric cancer.